The world’s first combined vaccine trials of Covid-19 registered on December 24, 2020 is soon to be conducted in accordance with the clinical trial’s protocol after ethics committee clearance. A vaccine combination of Sputnik V and the Oxford–AstraZeneca are yet to commence in former soviet republic Azerbaijan by February-end.
The research that uses the combination of the AZD1222 vaccine with the adenoviral vector Ad26 of the Sputnik V vaccine will be extensively held for over a period of six months in several countries with 100 participants enrolled in each.
The Russian Direct Investment Fund (RDIF), which is Russia’s sovereign wealth fund, has declared recently that the ministry of health of the republic of Azerbaijan has given a green signal on February 8 to perform the clinical trials.
RDIF, The Gamaleya Center, AstraZeneca and R-Pharm had earlier signed a pact of Intent with a goal to bring cooperation in vaccine development, which was announced in December 2020 during a meeting with Russian President Vladimir Putin. RDIF acts as a bridge to bring direct investments for the trial.
The research will determine the immunogenicity and safety of combined vaccine usage. This collaborative study is being developed with an approach to combat mutations that may occur in future.